ECCO 15 - ESMO 34

 
 
 

The joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology took place September 20 - 24, 2009, in Berlin, Germany.

 

Double-dose palonosetron achieves good control of CINV

Alice Goodman Read Article
Published: 10/14/09

Emesis basin
Emesis basin

A double dose of palonosetron controls chemotherapy-induced nausea and vomiting (CINV) more effectively than a single dose, according to a prospective evaluation of the 2 doses. Investigators undertook the study to determine whether the new 5-hydroxytryptamine receptor antagonist could achieve significant control in patients undergoing autologous stem cell transplant. They reported their findings at the ECCO 15 – 34th ESMO Multidisciplinary Congress held recently in Berlin, Germany. [Read Article]

Neutropenic events with ABVD higher than expected in HL patients

Alice Goodman Read Article
Published: 10/13/09

Hodgkin’s lymphoma (HL) patients in the United States and the European Union treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) had a considerably higher incidence of chemotherapy-induced neutropenic events than the expected rate according to EU guidelines, which are based on clinical trial data. The observational study covered the years 2002 to 2005, was sponsored by Amgen, and was presented at the ECCO 15 - 34th ESMO Joint Multidisciplinary Congress held in Berlin, Germany, in September. [Read Article]

Carfilzomib shows promise in relapsed MM

Alice Goodman Read Article
Published: 10/09/09

Two ongoing preliminary studies provide supportive evidence that carfilzomib, a novel proteasome inhibitor, is active and well tolerated in patients with relapsed and refractory multiple myeloma (MM). Both studies were presented at a poster session during the ECCO 15 - 34th ESMO Joint Multidisciplinary Congress in Berlin, Germany, September 20-24. [Read Article]

Vorinostat demonstrates consistent safety

Alice Goodman Read Article
Published: 10/07/09

Vorinostat demonstrates safety and tolerability alone and in combination with other systemic treatments for a wide range of solid and hematologic malignancies, according to a study of collated data from the vorinostat clinical trial program. Investigators presented the safety data in a poster at the ECCO 15 - 34th ESMO Multidisciplinary Congress. The data suggest that a supratherapeutic single dose (800 mg) of this orally active histone deacetylase inhibitor does not prolong ventricular repolarization to a significant degree. [Read Article]

Bendamustine matches fludarabine in second-line CLL treatment

Alice Goodman Read Article
Published: 10/05/09

 Peripheral blood smear showing CLL
Peripheral blood smear
showing CLL

Bendamustine provides comparable efficacy to fludarabine in patients with chronic lymphocytic leukemia (CLL) who relapse during or after chlorambucil treatment. Bendamustine, which is FDA-approved for CLL, should be considered a viable alternative to fludarabine in this setting, according to results of a recent prospective, randomized study presented at the ECCO 15 - 34th ESMO Multidisciplinary Congress. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}